Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2022-07-29 Purchase |
2022-08-02 5:02 pm |
Talaris Therapeutics Inc. | TALS | Requadt Scott Chief Executive Officer |
39,382 | $4.25 | $167,374 | 958,446 (Indirect Direct) |
View |
| 2022-07-26 Purchase |
2022-07-28 7:52 pm |
Talaris Therapeutics Inc. | TALS | Requadt Scott Chief Executive Officer |
8,618 | $4.2436 | $36,571 | 919,064 (Indirect Direct) |
View |
| 2022-07-22 Purchase |
2022-07-26 7:38 pm |
Talaris Therapeutics Inc. | TALS | Requadt Scott Chief Executive Officer |
9,444 | $3.7497 | $35,412 | 910,446 (Indirect Direct) |
View |
| 2022-07-19 Purchase |
2022-07-25 7:35 pm |
Talaris Therapeutics Inc. | TALS | Nader Francois Director |
138,500 | $3.6103 | $500,020 | 1,160,796 (Indirect Direct) |
View |
| 2021-05-11 Purchase |
2021-05-14 06:15 am |
Talaris Therapeutics Inc. | TALS | Clarus Lifesciences III L.P. Clarus Ventures III GP L.P. Blackstone Clarus III L.L.C. Blackstone Clarus GP L.P. Blackstone Holdings I L.P. Blackstone Holdings II L.P. Blackstone Holdings I/II GP L.L.C. Blackstone Group Inc Blackstone Group Management L.L.C. SCHWARZMAN STEPHEN A 10% Owner |
30,000 | $17 | $510,000 | 160,044 (Indirect) |
View |
| 2021-05-11 Purchase |
2021-05-13 9:59 pm |
Talaris Therapeutics Inc. | TALS | Clarus Defined Exit I L.P. Clarus DE II L.P. Clarus IV-A L.P. Clarus IV-B L.P. Clarus IV-C L.P. Clarus IV-D L.P. Clarus Ventures DE GP L.P. Clarus IV GP L.P. Blackstone Clarus DE L.L.C. Blackstone Clarus GP L.L.C. 10% Owner |
30,000 | $17 | $510,000 | 160,044 (Indirect) |
View |
| 2021-05-11 Purchase |
2021-05-11 8:29 pm |
Talaris Therapeutics Inc. | TALS | Agarwala Sandip Director 10% Owner |
235,000 | $17 | $3,995,000 | 3,220,775 (Indirect) |
View |
| 2021-05-11 Purchase |
2021-05-11 8:29 pm |
Talaris Therapeutics Inc. | TALS | Longitude Capital Partners III LLC Longitude Venture Partners III L.P. ENRIGHT PATRICK G Tammenoms Bakker Juliet 10% Owner |
235,000 | $17 | $3,995,000 | 3,220,775 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2022-07-21 Other |
2022-07-25 7:35 pm |
N/A N/A |
Talaris Therapeutics Inc. | TALS | Nader Francois Director |
386,932 | $0 | 1,160,796 (Indirect) |
View |
| 2022-06-09 Option Award |
2022-06-13 6:20 pm |
N/A 2032-06-08 |
Talaris Therapeutics Inc. | TALS | MCDADE MARK Director |
14,501 | $0 | 14,501 (Direct) |
View |
| 2022-06-09 Option Award |
2022-06-13 6:16 pm |
N/A 2032-06-08 |
Talaris Therapeutics Inc. | TALS | Shah Gaurav Director |
14,501 | $0 | 14,501 (Direct) |
View |
| 2022-06-09 Option Award |
2022-06-13 6:16 pm |
N/A 2032-06-08 |
Talaris Therapeutics Inc. | TALS | Smith Karen L. Director |
14,501 | $0 | 14,501 (Direct) |
View |
| 2022-06-09 Option Award |
2022-06-13 6:15 pm |
N/A 2032-06-08 |
Talaris Therapeutics Inc. | TALS | MACKAY GEOFFREY Director |
14,501 | $0 | 14,501 (Direct) |
View |
| 2022-06-09 Option Award |
2022-06-13 6:14 pm |
N/A 2032-06-08 |
Talaris Therapeutics Inc. | TALS | Nader Francois Director |
14,501 | $0 | 14,501 (Direct) |
View |
| 2022-06-09 Option Award |
2022-06-13 6:13 pm |
N/A 2032-06-08 |
Talaris Therapeutics Inc. | TALS | Agarwala Sandip Director 10% Owner |
14,501 | $0 | 14,501 (Direct) |
View |
| 2022-06-09 Option Award |
2022-06-13 6:11 pm |
N/A 2032-06-08 |
Talaris Therapeutics Inc. | TALS | Srivastava Sapna Director |
14,501 | $0 | 14,501 (Direct) |
View |
| 2022-05-16 Option Award |
2022-05-17 6:15 pm |
N/A 2032-05-15 |
Talaris Therapeutics Inc. | TALS | Smith Karen L. Director |
29,002 | $0 | 29,002 (Direct) |
View |
| 2021-11-17 Gift |
2022-02-02 6:04 pm |
N/A N/A |
Talaris Therapeutics Inc. | TALS | Ildstad Suzanne Chief Scientific Officer |
1,200,000 | $0 | 6,264,856 (Direct) |
View |
| 2022-02-01 Option Award |
2022-02-02 6:04 pm |
N/A 2032-01-31 |
Talaris Therapeutics Inc. | TALS | Ildstad Suzanne Chief Scientific Officer |
150,000 | $0 | 6,264,856 (Direct) |
View |
| 2022-02-01 Option Award |
2022-02-02 6:02 pm |
N/A 2032-01-31 |
Talaris Therapeutics Inc. | TALS | Krieger Nancy Chief Medical Officer |
190,000 | $0 | 190,000 (Direct) |
View |
| 2022-02-01 Option Award |
2022-02-02 6:01 pm |
N/A 2032-01-31 |
Talaris Therapeutics Inc. | TALS | Requadt Scott Chief Executive Officer |
500,000 | $0 | 1,401,002 (Direct) |
View |
| 2021-12-31 Option Award |
2022-02-02 6:01 pm |
N/A N/A |
Talaris Therapeutics Inc. | TALS | Requadt Scott Chief Executive Officer |
1,470 | $13 | 1,401,002 (Direct) |
View |
| 2022-02-01 Option Award |
2022-02-02 6:00 pm |
N/A 2032-01-31 |
Talaris Therapeutics Inc. | TALS | Fenton Mary Kay Chief Financial Officer |
200,000 | $0 | 201,000 (Direct) |
View |
| 2021-12-31 Option Award |
2022-02-02 6:00 pm |
N/A N/A |
Talaris Therapeutics Inc. | TALS | Fenton Mary Kay Chief Financial Officer |
1,000 | $13 | 201,000 (Direct) |
View |
| 2022-02-01 Option Award |
2022-02-02 6:00 pm |
N/A 2032-01-31 |
Talaris Therapeutics Inc. | TALS | Zdanowski Michael Chief Technology Officer |
200,000 | $0 | 201,470 (Direct) |
View |
| 2021-12-31 Option Award |
2022-02-02 6:00 pm |
N/A N/A |
Talaris Therapeutics Inc. | TALS | Zdanowski Michael Chief Technology Officer |
1,470 | $13 | 201,470 (Direct) |
View |
| 2021-12-15 Gift |
2021-12-16 4:05 pm |
N/A N/A |
Talaris Therapeutics Inc. | TALS | Nader Francois Director |
59,520 | $0 | 336,167 (Indirect) |
View |
| 2021-05-11 Conversion |
2021-05-14 06:15 am |
N/A N/A |
Talaris Therapeutics Inc. | TALS | Clarus Lifesciences III L.P. Clarus Ventures III GP L.P. Blackstone Clarus III L.L.C. Blackstone Clarus GP L.P. Blackstone Holdings I L.P. Blackstone Holdings II L.P. Blackstone Holdings I/II GP L.L.C. Blackstone Group Inc Blackstone Group Management L.L.C. SCHWARZMAN STEPHEN A 10% Owner |
51,176,706 | $0 | 160,044 (Indirect) |
View |
| 2021-05-11 Conversion |
2021-05-13 9:59 pm |
N/A N/A |
Talaris Therapeutics Inc. | TALS | Clarus Defined Exit I L.P. Clarus DE II L.P. Clarus IV-A L.P. Clarus IV-B L.P. Clarus IV-C L.P. Clarus IV-D L.P. Clarus Ventures DE GP L.P. Clarus IV GP L.P. Blackstone Clarus DE L.L.C. Blackstone Clarus GP L.L.C. 10% Owner |
51,176,706 | $0 | 160,044 (Indirect) |
View |
| 2021-05-11 Conversion |
2021-05-11 8:29 pm |
N/A N/A |
Talaris Therapeutics Inc. | TALS | Agarwala Sandip Director 10% Owner |
5,971,550 | $0 | 3,220,775 (Indirect) |
View |
| 2021-05-11 Conversion |
2021-05-11 8:29 pm |
N/A N/A |
Talaris Therapeutics Inc. | TALS | Longitude Capital Partners III LLC Longitude Venture Partners III L.P. ENRIGHT PATRICK G Tammenoms Bakker Juliet 10% Owner |
5,971,550 | $0 | 3,220,775 (Indirect) |
View |
Ownership |
2021-05-06 9:34 pm |
N/A N/A |
Talaris Therapeutics Inc. | TALS | Clarus Lifesciences III L.P. Clarus Ventures III GP L.P. Blackstone Clarus III L.L.C. Blackstone Clarus GP L.P. Blackstone Holdings I L.P. Blackstone Holdings II L.P. Blackstone Holdings I/II GP L.L.C. Blackstone Group Inc Blackstone Group Management L.L.C. SCHWARZMAN STEPHEN A 10% Owner |
0 | $0 | 8,059,315 (Indirect) |
View |
Ownership |
2021-05-06 9:31 pm |
N/A N/A |
Talaris Therapeutics Inc. | TALS | Agarwala Sandip Director 10% Owner |
0 | $0 | 2,985,775 (Indirect) |
View |
Ownership |
2021-05-06 9:29 pm |
N/A 2031-02-21 |
Talaris Therapeutics Inc. | TALS | Srivastava Sapna Director |
0 | $0 | 76,635 (Direct) |
View |
Ownership |
2021-05-06 9:28 pm |
N/A N/A |
Talaris Therapeutics Inc. | TALS | Clarus Defined Exit I L.P. Clarus DE II L.P. Clarus IV-A L.P. Clarus IV-B L.P. Clarus IV-C L.P. Clarus IV-D L.P. Clarus Ventures DE GP L.P. Clarus IV GP L.P. Blackstone Clarus DE L.L.C. Blackstone Clarus GP L.L.C. 10% Owner |
0 | $0 | 8,059,315 (Indirect) |
View |
Ownership |
2021-05-06 9:25 pm |
N/A N/A |
Talaris Therapeutics Inc. | TALS | Longitude Capital Partners III LLC Longitude Venture Partners III L.P. ENRIGHT PATRICK G Tammenoms Bakker Juliet 10% Owner |
0 | $0 | 2,985,775 (Indirect) |
View |
Ownership |
2021-05-06 9:25 pm |
N/A N/A |
Talaris Therapeutics Inc. | TALS | Requadt Scott See Remarks |
0 | $0 | 1,596,050 (Direct) |
View |
Ownership |
2021-05-06 9:22 pm |
N/A 2028-12-20 |
Talaris Therapeutics Inc. | TALS | MACKAY GEOFFREY Director |
0 | $0 | 76,788 (Direct) |
View |
Ownership |
2021-05-06 9:21 pm |
N/A N/A |
Talaris Therapeutics Inc. | TALS | Krieger Nancy Chief Medical Officer |
0 | $0 | 392,761 (Direct) |
View |
Ownership |
2021-05-06 9:18 pm |
N/A 2030-12-04 |
Talaris Therapeutics Inc. | TALS | Shah Gaurav Director |
0 | $0 | 76,635 (Direct) |
View |
Ownership |
2021-05-06 9:18 pm |
N/A 2030-10-02 |
Talaris Therapeutics Inc. | TALS | Zdanowski Michael Chief Technology Officer |
0 | $0 | 224,298 (Direct) |
View |
Ownership |
2021-05-06 9:18 pm |
N/A N/A |
Talaris Therapeutics Inc. | TALS | Nader Francois Director |
0 | $0 | 477,060 (Direct) |
View |
Ownership |
2021-05-06 9:16 pm |
N/A N/A |
Talaris Therapeutics Inc. | TALS | Ildstad Suzanne Chief Scientific Officer 10% Owner |
0 | $0 | 6,114,856 (Direct) |
View |
Ownership |
2021-05-06 9:14 pm |
N/A 2031-02-21 |
Talaris Therapeutics Inc. | TALS | Fenton Mary Kay Chief Financial Officer |
0 | $0 | 364,485 (Direct) |
View |